Relapse prevention with antidepressant drug treatment in depressive disorders: A systematic review

Lancet

Volumn 361, Issue 9358, 2003, Pages 653-661

  Geddes, John R ^a   Carney, Stuart M ^a   Davies, Christina ^b   Furukawa, Toshiaki A ^c   Kupfer, David J ^d   Frank, Ellen ^d   Goodwin, Guy M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROPHYLAXIS; RELAPSE; RISK;

EID: 0037460745     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12599-8     Document Type: Article

References (55)

1. Murray C.J., Lopez A.D. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 349:1997;1436-1442.
2. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 349:1997;1498-1504.
3. Geddes J.R., Butler R. Depressive disorders in adults. Clinical Evidence. 2002;BMJ Publishing Group, London.
4. Paykel E.S., Priest R.G. Recognition and management of depression in general practice: consensus statement. BMJ. 305:1992;1198-1202.
5. Depression Guideline Panel. Depression in Primary Care: volume 2 treatment of major depression. Maryland, Agency for Health Care Policy and Research, US Department of Health and Human Services. Rockville, 1993.
6. Anderson I.M., Nutt D.J., Deakin J.F. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol. 14:2000;3-20.
7. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 157:(suppl 4):2000;1-45.
8. Hirschfeld R.M., Keller M.B., Panico S., et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA. 277:1997;333-340.
9. Furukawa T.A., Guyatt G.H., Grifitth L.E. Can we individualize the number needed to treat (NNT)? An empirical study of summary effect measures in meta-analyses. Int J Epidemiol. 31:2002;72-76.
10. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 308:1994;81-106.
11. Yusuf S., Collins R., Peto R., et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction, and side-effects from 33 randomized controlled trials. Eur Heart J. 6:1985;556-585.
12. Frank E., Prien R.F., Jarrett R.B., et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 48:1991;851-855.
13. Alexopoulos G.S., Meyers B.S., Young R.C., et al. Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry. 57:2000;285-290.
14. Bialos D., Giller E., Jatlow P., Docherty J., Harkness L. Recurrence of depression after discontinuation of long-term amitriptyline treatment. Am J Psychiatry. 139:1982;325-329.
15. Cook B.L., Helms P.M., Smith R.E., Tsai M. Unipolar depression in the elderly. Reoccurrence on discontinuation of tricyclic antidepressants. J Affect Disord. 10:1986;91-94.
16. Coppen A., Ghose K., Montgomery S., Rama R.V., Bailey J., Jorgensen A. Continuation therapy with amitriptyline in depression. Br J Psychiatry. 133:1978;28-33.
17. Davidson J., Raft D. Use of phenelzine in continuation therapy. Neuropsychobiology. 11:1984;191-194.
18. Doogan D.P., Caillard V. Sertraline in the prevention of depression. Br J Psychiatry. 160:1992;217-222.
19. Eric L. A prospective double-blind comparative multi-centre study of paroxetine in preventing recurrent major depressive episodes. Biol Psychiatry. 29:1991;11-14.
20. Feiger A.D., Bielski R.J., Bremner J., et al. Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. Int Clin Psychopharmacol. 14:1999;19-28.
21. Frank E., Kupfer D.J., Perel J.M., et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 47:1990;1093-1099.
22. Georgotas A., McCue R.E., Cooper T.B. A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry. 46:1989;783-786.
23. Glen A.I., Johnson A.L., Shepherd M. Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a randomized, double-blind, controlled trial. Psychol Med. 14:1984;37-50.
24. Harrison W., Rabkin J., Stewart J.W., et al. Phenelzine for chronic depression: a study of continuation treatment. J Clin Psychiatry. 47:1986;346-349.
25. Hochstrasser B., Isaksen P.M., Koponen H., et al. Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy. Br J Psychiatry. 178:2001;304-310.
26. Jenkins S.W., Robinson D.S., Fabre L.F. Gepirone treatment of major depression. J Clin Psychopharmacol. 10:1991;77-85.
27. Kane J.M., Quitkin F.M., Rifkin A., Ramos L. jr, Nayak D.D., Howard A. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry. 39:1982;1065-1069.
28. Keller M.B., Kocsis J.H., Thase M.E., et al. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA. 280:1998;1665-1672.
29. Kishimoto A., Mizukawa R., Matsuzaki F., et al. Prophylactic effect of mianserin on recurrent depression. Acta Psychiatr Scand. 89:1994;46-51.
30. Klerman G.L., Dimascio A., Weissman M., Prusoff B., Paykel E.S. Treatment of depression by drugs and psychotherapy. Am J Psychiatry. 131:1974;186-191.
31. Klysner R., Bent-Hansen J., Hansen H.L., et al. Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br J Psychiatry. 181:2002;29-35.
32. Kocsis J.H., Friedman R.A., Markowitz J.C., et al. Maintenance therapy for chronic depression. A controlled clinical trial of desipramine. Arch Gen Psychiatry. 53:1996;769-774.
33. Kupfer D.J., Frank E., Perel J.M., et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 49:1992;769-773.
34. Lendresse P.H., Chen M.C., LeMarie J.C. Traitement prolongé par nomifensine 75mg dans les états dépressifs neurotiques et reactionnels. Psychiatrie Francaise. 16:1985;156-158.
35. Mindham R.H., Howland C., Shepherd M. Continuation therapy with tricyclic antidepressants in depressive illness. Lancet. 2:1972;854-855.
36. Montgomery S.A., Dufour H., Brion S., et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry. 3:(suppl):1988;69-76.
37. Montgomery S.A., Rasmussen J.G. Citalopram 20 mg, citalopram 40 mg and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol. 6:(suppl 5):1992;71-73.
38. Montgomery S.A., Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol. 8:1993;189-195.
39. Prien R.F., Kupfer D.J., Mansky P.A., et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry. 41:1984;1096-1104.
40. How long should the elderly take antidepressants? A double-blind placebo-controlled study of continuation/prophylaxis therapy with dothiepin. Br J Psychiatry. 162:1993;175-182.
41. Reimherr F.W., Amsterdam J.D., Quitkin F.M., et al. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry. 155:1998;1247-1253.
42. Reynolds C.F., Frank E., Perel J.M., et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA. 281:1999;39-45.
43. Robert P., Montgomery S.A. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol. 10:(suppl 1):1995;29-35.
44. Robinson D.S., Lerfald S.C., Bennett B., et al. Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: a double-blind placebo-controlled discontinuation study. Psychopharmacol Bull. 27:1991;31-39.
45. Rouillon F., Phillips R., Serrurier D., Ansart E., Gerard M.J. Rechutes de dépression unipolaire et efficacité de la maprotiline. Encephale. 15:1989;527-534.
46. Rouillon F., Berdeaux G., Bisserbe J.C., et al. Prevention of recurrent depressive episodes with milnacipran: consequences on quality of life. J Affect Disord. 58:2000;171-180.
47. Stein M.K., Rickels K., Weise C.C. Maintenance therapy with amitriptyline: a controlled trial. Am J Psychiatry. 137:1980;370-371.
48. Terra J.L., Montgomery S.A. Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 13:1998;55-62.
49. Versiani M., Mehilane L., Gaszner P., Arnaud C.R. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry. 60:1999;400-406.
50. Viguera A.C., Baldessarini R.J., Friedberg J. Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry. 5:1998;293-306.
51. Goodwin G.M. Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder. Br J Psychiatry. 164:1994;149-152.
52. Suppes T., Baldessarini R.J., Faedda G.L., Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry. 48:1991;1082-1088.
53. Burgess S, Geddes JR, Townsend E, Jamison K, Hawton K, Goodwin GM. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev 2001; (3): CD003013.
54. Mander A.J., Loudon J.B. Rapid recurrence of mania following abrupt discontinuation of lithium. Lancet. 2:1988;15-17.
55. Clarke M.J., Stewart L.A. Obtaining data from randomised controlled trials: how much do we need for reliable and informative meta-analyses? BMJ. 309:1994;1007-1010.